Orchid Pharma to exit its Chinese JV

Orchid Pharma to exit its Chinese JV

Strategy to consolidate manufacturing operations in India

Chennai, India | November 9, 2012

Chennai-based global pharma major, Orchid Chemicals & Pharmaceuticals Ltd. (Orchid Pharma) today said that it was exiting its 50:50 manufacturing joint venture in China.

The 50% stake that Orchid holds in the Joint Venture (JV) company (NCPC-Orchid Pharmaceuticals) will be transferred to the partner company (NCPC) for a total cash consideration of USD 13.9 million (RMB 87.5 million).

Orchid had in 2002 entered into a 50:50 JV with North China Pharmaceutical Corporation (NCPC) to set up a Cephalosporin API manufacturing facility located in Shijiazhuang, China.

Commenting on the development, Orchid's Chairman & Managing Director Mr K Raghavendra Rao said, "With the local Chinese players fast integrating, the operating conditions have grown quite competitive in China. Moreover, the products that the JV manufactures and markets in the local Chinese market have reached a mature stage resulting in flat growth prospects going forward. Hence, it was a prudent decision to relinquish our stake to the partner and exit the JV".

Suggested Articles

Dr. Reddy’s says it has been told the FDA will not take regulatory action at its sterile formulations plant in Duvvada, Visakhapatnam.

The end is near for a GlaxoSmithKline OTC plant in Pennsylvania and its 260 employees. In fact, it has a date. 

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.